Massachusetts General Hospital | MassGeneral Hospital for Children

Biography

Dr. Sam Moskowitz received his AB from Princeton Univ. in 1986 and MD magna cum laude in 1994 from Harvard Medical School. His research interests lie in the investigation of pediatric lung disease, particularly in cystic fibrosis and lung infection by Pseudomonas. He has held academic and clinical positions at Univ. of Washington School of Medicine and Seattle Children's Hospital, and is currently affiliated with MassGeneral Hospital for Children and Harvard Medical School.

ResearchMy laboratory has four major projects focused on regulation of antibiotic resistance mechanisms and coordinately-controlled virulence processes relevant to Pseudomonas infection of vertebrate hosts.

Publications

View my most recent publications at PubMed

1: Moskowitz SM, Brannon MK, Dasgupta N, Pier M, Sgambati N, Miller AK, Selgrade SE, Miller SI, Denton M, Conway SP, Johansen HK, H?iby N. PmrB mutations promote polymyxin resistance of Pseudomonas aeruginosa isolated from colistin-treatedcystic fibrosis patients. Antimicrob Agents Chemother. 2012 Feb;56(2):1019-30.2: Miller AK, Brannon MK, Stevens L, Johansen HK, Selgrade SE, Miller SI, H?ibyN, Moskowitz SM. PhoQ mutations promote lipid A modification and polymyxinresistance of Pseudomonas aeruginosa found in colistin-treated cystic fibrosispatients. Antimicrob Agents Chemother. 2011 Dec;55(12):5761-9.3: Moskowitz SM, Emerson JC, McNamara S, Shell RD, Orenstein DM, Rosenbluth D,Katz MF, Ahrens R, Hornick D, Joseph PM, Gibson RL, Aitken ML, Benton WW, BurnsJL. Randomized trial of biofilm testing to select antibiotics for cystic fibrosisairway infection. Pediatr Pulmonol. 2011 Feb;46(2):184-92.4: Moskowitz SM, Garber E, Chen Y, Clock SA, Tabibi S, Miller AK, Doctor M,Saiman L. Colistin susceptibility testing: evaluation of reliability for cysticfibrosis isolates of Pseudomonas aeruginosa and Stenotrophomonas maltophilia. JAntimicrob Chemother. 2010 Jul;65(7):1416-23.5: Johansen HK, Moskowitz SM, Ciofu O, Pressler T, H?iby N. Spread of colistinresistant non-mucoid Pseudomonas aeruginosa among chronically infected Danishcystic fibrosis patients. J Cyst Fibros. 2008 Sep;7(5):391-7.6: Moskowitz SM, Ernst RK, Miller SI. PmrAB, a two-component regulatory systemof Pseudomonas aeruginosa that modulates resistance to cationic antimicrobialpeptides and addition of aminoarabinose to lipid A. J Bacteriol. 2004Jan;186(2):575-9.

Research of Sam Moskowitz, MD

The Moskowitz research program at MGHfC focuses on chronic airway infection and host-pathogen interactions in cystic fibrosis (CF), encompassing the fields of microbiology, biochemistry, immunology, epithelial biology, bacterial and eukaryotic genetics, and pulmonary medicine.

Breakthrough cystic fibrosis drug gives hope, transforms lives

Praised by experts as a breakthrough for patients with a particular form of cystic fibrosis, ivacaftor was approved by the United States Food and Drug Administration (FDA) in January 2012 and is the first of its kind to treat the underlying defects of the disease, rather than manage its symptoms.